Abstract:WT1, a tumor suppressor gene originally found to be responsible for the development of childhood kidney tumor, is now thought to be also involved in the pathogenesis of human leukemia. Since WT1 is reported to be expressed at much higher level in bone marrow cells from MDS and all subtypes of leukemia comparing to the normal blood cells, it is proposed to be a “panleukemic marker” for the diagnosis of leukemia. The expression level of WT1 may also have significance in predicting prognosis and monitoring relapse. However, this notion on the usage of WT1 is somehow still remaining controversial because WT1 is also expressed to a certain level in a small population of CD 34 + cells. To measure more accurately the expression level of WT1 in bone marrow cells of acute leukemia patients (ALs). Real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) method was established for detecting WT1 and GAPDH expression levels in BM of 108 ALs and 23 non-leukemias patients by LightCycler. Besides, BM cells of 15 AL patients, including a total of 111 BM specimen taken during the follow-up after allo-BMT were also subject to RQ-RT-PCR. Normalized WT1 expression level (WT1 N ) was determined as a ratio between WT1 and GAPDH times 10 4 . The expression levels of WT1 N in 70 newly diagnosed ALs and 11 relapsed ALs were statistically higher than those of 23 ALs with complete remission(CR) and 23 non-leukemic controls (108.50±137.08 and 135.00±107.87 vs 3.88±3.09 and 2.23±3.19). Statistical differences were found neither between the CR group and control group, nor between the newly diagnosed group and relapsed group. Of the 70 newly diagnosed ALs, WT1 N expression level of acute granulocytic leukemias was significantly higher than that of acute monocytic leukemias, but there were no statistic differences among the M 1 , M 2 , M 3 and ALL subtypes. Furthermore, the WT1 N levels were not correlated to WBC counts in peripheral blood, the blast ratio in the BM and the expression of MDR-1 at presentation, but do correlated to the leukemia cell chromosome karyotypes. The dynamic changes of WT1 N levels in 2 patients during treatment suggested that WT1 expression levels could be used to monitor the disease outcome and predict relapse. In gereral, the dynamic curves of WT1 level following allo-BMT were consistemt with the tendnecy of changes in expression levels of corresponding fusion genefor MRD monitoring. A re-increment of WT1 expression level during follow-up could be detected 40 to 180 days earlier to hematological relapse. These studies have provided strong evidence suggesting that WT1 expression levels in cells of AL patients were markedly higher than an undetectable or a marginal level expressed in non-leukemias patients. WT1 can indeed be a marker for evaluating therapy efficacy in leukemias. WT1 expression levels in leukemia patients following allo-BMT measured by real time RT-PCR can be a useful tool for monitoring MRD and warning the clinical relapse during follow-up.

[One-Step Real-Time Fluorescence Quantitative PCR for Detecting WT1 Mrna Expression in Leukemia].

The Effect of WT1 Expression on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia

Clinical Significance of Real - Time Fluorescent Quantitative PCR for Detection of WT1 Gene Expression in Leukemia Patients

Detection of WT1 Gene by Real-Time Quantitative PCR in Childhood Leukemia

Fluorescence Quantitative PCR Detection of WT1 Gene Expression in Peripheral Blood of Patients with Acute Leukemias and Its Clinical Implications

The detection of WT1 gene expression in peripheral blood of acute leukemia patients with fluorescence quantitative RT-PCR

Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance]

[Detection of WT1 Expression in Bone Marrow of Acute Leukemia Patients with Real-Time Quantitative RT-PCR].

Detection of Wt1 Expression in Bone Marrow Cells of Acute Leukemia Patients and During Their Follow-Up after Allo-Bmt Using Real-Time Quantitative Rt-Pcr.

Simultaneous detection of WT1 and MDR1 gene expression in acute leukemia patients by a multiplex real time quantitative PCR method

Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients]

[Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia]

Significance of Dynamic Detection of WT1 Expression on Monitoring Minimal Residual Disease in Leukemia Patients Following Allogeneic Bone Marrow Transplantation

Quantitative assessment of wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia

The Expression of WT1 Gene in Acute Leukemia Patients

Expression of WT1 Gene in Acute Leukemia in Children and Its Clinical Significance

Expression of WT1 gene in myeloproliferative disorders and its clinical significance

[Expression of WT1 Gene in Children with Acute Myeloid Leukemia].

Expression of WT1 Gene in Acute Leukemia and Its Clinical Significance

Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation

Wilms’ Tumor Gene (WT1) Expression and Minimal Residual Disease in Acute Myeloid Leukemia